Warning! GuruFocus detected
1 Severe warning sign
with 1733.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Apex Biotechnology Corp
ISIN : TW0001733004
Description
Apex Biotechnology Corp engages mainly in the research, development, production, manufacturing, and selling of biochemical testing instruments and detection strips, and the trade of products and components relevant to the core business. Its products offer Diabetes Care, Home Diagnostics, and Point-of-Care Clinical and Laboratory. Its product offerings include Eclipse plus multipurpose analyzer, Glucosure HT blood glucose monitoring system, and HemoSmart GOLD hemoglobin screening system among others. Company operates in Taiwan, USA, Italy, Austria, China , Others. Majority of revenue is from USA.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.6 | |||||
| Equity-to-Asset | 0.75 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | 0.75 | |||||
| Interest Coverage | 35.29 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 5.06 | |||||
| Beneish M-Score | -2.62 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -2.9 | |||||
| 3-Year EBITDA Growth Rate | -7.3 | |||||
| 3-Year EPS without NRI Growth Rate | -12.6 | |||||
| 3-Year FCF Growth Rate | 27 | |||||
| 3-Year Book Growth Rate | 1.3 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.04 | |||||
| 9-Day RSI | 52.25 | |||||
| 14-Day RSI | 58.89 | |||||
| 3-1 Month Momentum % | 2.49 | |||||
| 6-1 Month Momentum % | 3.52 | |||||
| 12-1 Month Momentum % | -8.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.44 | |||||
| Quick Ratio | 2.05 | |||||
| Cash Ratio | 1.25 | |||||
| Days Inventory | 187.75 | |||||
| Days Sales Outstanding | 70.79 | |||||
| Days Payable | 44.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.28 | |||||
| Dividend Payout Ratio | 0.87 | |||||
| 3-Year Dividend Growth Rate | 0.2 | |||||
| Forward Dividend Yield % | 3.28 | |||||
| 5-Year Yield-on-Cost % | 4.47 | |||||
| Shareholder Yield % | 3.76 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 28.15 | |||||
| Operating Margin % | 6.94 | |||||
| Net Margin % | 6.91 | |||||
| FCF Margin % | 16.14 | |||||
| ROE % | 7.22 | |||||
| ROA % | 5.48 | |||||
| ROIC % | 7.08 | |||||
| 3-Year ROIIC % | 107.02 | |||||
| ROC (Joel Greenblatt) % | 11.33 | |||||
| ROCE % | 8.29 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 26.11 | |||||
| Forward PE Ratio | 28.43 | |||||
| PE Ratio without NRI | 26.09 | |||||
| Shiller PE Ratio | 23.16 | |||||
| Price-to-Owner-Earnings | 10.84 | |||||
| PS Ratio | 1.8 | |||||
| PB Ratio | 1.82 | |||||
| Price-to-Tangible-Book | 1.86 | |||||
| Price-to-Free-Cash-Flow | 11.16 | |||||
| Price-to-Operating-Cash-Flow | 10.16 | |||||
| EV-to-EBIT | 18.38 | |||||
| EV-to-EBITDA | 13 | |||||
| EV-to-Revenue | 1.56 | |||||
| EV-to-FCF | 9.77 | |||||
| Price-to-GF-Value | 1.33 | |||||
| Price-to-Projected-FCF | 0.94 | |||||
| Price-to-Median-PS-Value | 1.08 | |||||
| Price-to-Graham-Number | 1.47 | |||||
| Price-to-Net-Current-Asset-Value | 3.17 | |||||
| Price-to-Net-Cash | 1657.5 | |||||
| Earnings Yield (Greenblatt) % | 5.44 | |||||
| FCF Yield % | 9.03 | |||||
| Forward Rate of Return (Yacktman) % | 3.57 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Apex Biotechnology Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 1,852.211 | ||
| EPS (TTM) (NT$) | 1.27 | ||
| Beta | -0.1 | ||
| 3-Year Sharpe Ratio | 0.22 | ||
| 3-Year Sortino Ratio | 0.4 | ||
| Volatility % | 44.82 | ||
| 14-Day RSI | 58.89 | ||
| 14-Day ATR (NT$) | 0.748964 | ||
| 20-Day SMA (NT$) | 32.7 | ||
| 12-1 Month Momentum % | -8.86 | ||
| 52-Week Range (NT$) | 27.05 - 37.8 | ||
| Shares Outstanding (Mil) | 99.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Apex Biotechnology Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Apex Biotechnology Corp Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Apex Biotechnology Corp Frequently Asked Questions
What is Apex Biotechnology Corp(TPE:1733)'s stock price today?
The current price of TPE:1733 is NT$33.15. The 52 week high of TPE:1733 is NT$37.80 and 52 week low is NT$27.05.
When is next earnings date of Apex Biotechnology Corp(TPE:1733)?
The next earnings date of Apex Biotechnology Corp(TPE:1733) is .
Does Apex Biotechnology Corp(TPE:1733) pay dividends? If so, how much?
The Dividend Yield %  of Apex Biotechnology Corp(TPE:1733) is 3.28% (As of Today), Highest Dividend Payout Ratio of Apex Biotechnology Corp(TPE:1733) was 70.03. The lowest was 0.4. And the median was 0.93. The  Forward Dividend Yield % of Apex Biotechnology Corp(TPE:1733) is 3.28%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers